DIFFERENTIAL IMPACT OF PERIODONTAL TREATMENT STRATEGIES DURING PREGNANCY ON PERINATAL OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Author(s):  
Quynh-Anh Le ◽  
Guy D. Eslick ◽  
Kimberly Mathieu Coulton ◽  
Rahena Akhter ◽  
Samantha Lain ◽  
...  
2020 ◽  
Author(s):  
Pengming Sun ◽  
Hangjing Gao ◽  
Xiqi Huang ◽  
Huanrui Zheng ◽  
Hongning Cai ◽  
...  

Author(s):  
Rafael Paschoal ESTEVES LIMA ◽  
Andressa Rafaela Silva ATANAZIO ◽  
Fernando Oliveira COSTA ◽  
Fabiano Araújo CUNHA ◽  
Lucas Guimarães ABREU

2021 ◽  
Vol 10 (11) ◽  
pp. 2490
Author(s):  
Giulio Francesco Romiti ◽  
Bernadette Corica ◽  
Gregory Y. H. Lip ◽  
Marco Proietti

Background: In patients with COVID-19, cardiovascular complications are common and associated with poor prognosis. Among these, an association between atrial fibrillation (AF) and COVID-19 has been described; however, the extent of this relationship is unclear. The aim of this study is to investigate the epidemiology of AF in COVID-19 patients and its impact on all-cause mortality. Methods: A systematic review and meta-analysis were performed and reported according to PRISMA guidelines, and a protocol for this study was registered on PROSPERO (CRD42021227950). PubMed and EMBASE were systematically searched for relevant studies. A random-effects model was used to estimate pooled odds ratios (OR) and 95% confidence intervals (CI). Results: Overall, 31 studies were included in the analysis, with a total number of 187,716 COVID-19 patients. The prevalence of AF was found to be as high as 8% of patients with COVID-19 (95% CI: 6.3–10.2%, 95% prediction intervals (PI): 2.0–27.1%), with a high degree of heterogeneity between studies; a multiple meta-regression model including geographical location, age, hypertension, and diabetes showed that these factors accounted for more than a third of the heterogeneity. AF COVID-19 patients were less likely to be female but more likely older, hypertensive, and with a critical status than those without AF. Patients with AF showed a significant increase in the risk of all-cause mortality (OR: 3.97, 95% CI: 2.76–5.71), with a high degree of heterogeneity. A sensitivity analysis focusing on new-onset AF showed the consistency of these results. Conclusions: Among COVID-19 patients, AF is found in 8% of patients. AF COVID-19 patients are older, more hypertensive, and more likely to have a critical status. In COVID-19 patients, AF is associated with a 4-fold higher risk of death. Further studies are needed to define the best treatment strategies to improve the prognosis of AF COVID-19 patients.


2021 ◽  
Vol 224 (2) ◽  
pp. S216
Author(s):  
Ahmed A. Nassr ◽  
Hessami Kamran ◽  
Sherif Shazly ◽  
Nazlisadat Meshinchiasl ◽  
Romain Corroenne ◽  
...  

Author(s):  
Barbara Chmielewska ◽  
Imogen Barratt ◽  
Rosemary Townsend ◽  
Erkan Kalafat ◽  
Jan van der Meulen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document